Table 2 Clinicopathological Features in Each Molecular Group
Conventional | EBV-positive | MSI-high | |
|---|---|---|---|
(n = 429) | (n = 32) | (n = 53) | |
Sex | |||
Male | 290 (68%) | 24 (75%) | 33 (62%) |
Female | 139 (32%) | 8 (25%) | 20 (38%) |
Age, median (years, range) | 65 (27–88) | 63 (45–88) | 64 (34–82) |
Tumor site | *aP < 0.001 | ||
Lower 1/3 | 287 (67%) | 4 (13%) | 41 (77%) |
Middle 1/3 | 85 (20%) | 11 (34%) | 7 (13%) |
Upper 1/3 | 57 (13%) | 17 (53%) | 5 (9%) |
Histologic type | *bP = 0.006 | ||
Tubular adenocarcinoma | 343 (80%) | 29 (91%) | 43 (81%) |
Poorly cohesive | 76 (18%) | 2 (6%) | 5 (9%) |
Mucinous carcinoma | 5 (1%) | 0 | 4 (8%) |
Undifferentiated | 5 (1%) | 1 (3%) | 1 (2%) |
Lauren | *aP = 0.029 | ||
Intestinal | 246 (57%) | 12 (38%) | 28 (53%) |
Diffuse | 183 (43%) | 20 (63%) | 25 (47%) |
Lymphatic invasion | *bP < 0.001 | ||
Present | 182 (42%) | 11 (34%) | 37 (70%) |
Depth of invasion (pT) | *bP = 0.031 | ||
pT1 (mucosa, submucosa) | 229 (53%) | 17 (53%) | 16 (30%) |
pT2 (muscularis proper) | 37 (9%) | 3 (9%) | 6 (11%) |
pT3 (subserosa) | 79 (18%) | 2 (6%) | 16 (30%) |
pT4 (serosa or beyond) | 84 (20%) | 10 (31%) | 15 (28%) |
Lymph node metastasis | |||
Present | 177 (41%) | 10 (31%) | 28 (53%) |
Tumor stage (pTNM) | *bP = 0.028 | ||
Stage I | 238 (55%) | 20 (63%) | 19 (36%) |
Stage II | 64 (15%) | 3 (9%) | 14 (26%) |
Stage III | 105 (24%) | 7 (22%) | 18 (34%) |
Stage IV | 22 (5%) | 2 (6%) | 2 (4%) |